Metastatic Pancreatic Adenocarcinoma During Pregnancy.

We present a rare case of metastatic pancreatic adenocarcinoma diagnosed antepartum. A high index of suspicion must be maintained to diagnose pancreatic cancer during pregnancy. We recommend a thorough history and physical and aggressive pursuit of sensitive imaging in patients with persistent symptoms. If pancreatic adenocarcinoma is diagnosed, a multidisciplinary approach that focuses on patient goals should be undertaken. The effect of pregnancy on tumor growth rates is unknown.

Laparoscopy for stage IV melanoma in two organs.

Metastatic melanoma remains a disease associated with poor outcomes. Traditionally, surgical intervention plays a minimal role in its treatment. However, more recent studies document that complete surgical resection of distant metastases is associated with 5-year survival rates of 15% to 30%. These rates are greater than that reported for single-agent or combination chemotherapy, biologic agents or immunotherapy. This case report outlines a unique presentation of stage IV melanoma within the gastrointestinal tract located in 2 different organs. On the basis of the patient's clinical findings, laparoscopic surgery was performed for palliation of intestinal obstruction and bleeding. This approach resulted in less postoperative pain, earlier mobilization, and a faster return to daily activities. To our knowledge, this case details the only known account that uses a laparoscopic approach to palliate stage IV melanoma at 2 synchronous sites; the stomach and small bowel. The literature regarding the treatment of metastatic melanoma is also briefly reviewed.

Laparoscopic total gastrectomy for Ménétrier's disease.

Most patients with Ménétrier's disease are treated nonoperatively with nutritional support, antacids, and pain medications. Surgical intervention is rarely required. We report the case of a 41-year-old male with HIV and hepatitis B who presented with weight loss, abdominal pain, nausea, and vomiting. A computed tomography scan of the abdomen showed diffuse gastric thickening without lymphadenopathy and an upper endoscopy revealed chronic gastritis and enlarged gastric folds without evidence of Helicobacter pylori. Multiple endoscopic biopsies showed chronic inflammation without malignancy. A laparoscopic assisted full thickness biopsy revealed foveolar hyperplasia consistent with Ménétrier's disease. Postoperatively, the patient's symptoms continued to worsen and were complicated by lower gastrointestinal bleeding secondary to gastric erosions. The patient did not experience any hematemesis, only melena. A laparoscopic total gastrectomy with a Roux-en-Y esophagojejunostomy was performed. The patient was discharged home on postoperative day 7 tolerating a postgastrectomy diet. His hematocrit stabilized and he remained asymptomatic at 16-month follow-up. Ménétrier's disease is a rare gastrointestinal entity that can be treated safely with minimally invasive skills. We report this case in detail and discuss Ménétrier's disease.

Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas.

BACKGROUND: Assessment of tumor burden changes is essential for the management of patients with neuroendocrine gastrointestinal (GI) tumors. Chromogranin A (CgA) is a tumor marker for such tumors; however, to the authors' knowledge, there is little information on whether serial assessments can assess changes in tumor burden. In this prospective study of patients with gastrinomas, serial changes in serum CgA levels were compared with changes in levels of the specific tumor marker gastrin to determine whether they reflected changes in tumor burden. METHODS: In 72 consecutive patients, the mean CgA and gastrin levels from three determinations were measured on each visit. Changes in markers were correlated with changes in tumor burden determined by imaging. By assessing daily changes, significance changes in CgA and gastrin levels were determined. RESULTS: During 103 follow-up visits (mean, 9.6 months), an increased tumor size occurred in 25% of patients, no change occurred in 62% of patients, and a decrease occurred in 13% of patients. In patients who had increasing tumor size, CgA levels increased numerically in 77% of patients, gastrin levels increased in 54% of patients, and the increases were significant in 60-80% of patients. In patients who had tumor stabilization, CgA levels in 63% of patients and gastrin levels in 73% of patients did not show a significant change. Decreased tumor size postresection showed a significant decrease in CgA and gastrin levels in all patients. The sensitivity of CgA and gastrin was as follows: sensitivity for detecting an increase, 62% for CgA and 31% for gastrin; sensitivity for detecting no change, 42% for CgA and 75% for gastrin; and sensitivity for detecting a decrease in tumor size, 85% for CgA and 85% for gastrin. The specificity varied from 53% to 99% for CgA and from 49% to 93% for gastrin. CONCLUSIONS: In patients with gastrinomas, serum CgA and gastrin levels varied considerably from day to day, and this must be taken into consideration. Both markers had low sensitivity and specificity for detecting tumor increases and stabilization. For large tumor decreases postresection, both markers had high sensitivity and specificity. The current results suggest that these markers do not have sufficient sensitivity to replace serial imaging studies for detecting important smaller changes in tumor burden in patients with gastrinomas.

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.

BACKGROUND: Malignant pancreatic endocrine tumors (PETs) have a poor prognosis and existing antitumor treatments are unsatisfactory. Recent studies have shown somatostatin analogues to have antitumor growth effects in patients with malignant PETs; however, to the authors' knowledge, little information exists regarding their efficacy or effect on survival in patients with progressive malignant gastrinoma, the most common symptomatic malignant PET. The purpose of the current study was to study prospectively the efficacy, safety, and effect on survival of long-term treatment with octreotide in consecutive patients with progressive malignant gastrinoma. METHODS: Fifteen consecutive patients with malignant gastrinoma with progressive hepatic metastases were studied. All patients underwent conventional imaging studies (computed tomography scan, magnetic resonance imaging, ultrasound, and, if needed, selective angiography) and somatostatin receptor scintigraphy prior to treatment and at 3-6-month intervals while receiving treatment. The patients all were treated initially with octreotide, 200 microg every 12 hours, and at last follow-up were being maintained on long-acting release octreotide, 20-30 mg every month. Tumor size and/or number were used to classify patient responses as either no tumor response or tumor response (stabilization or decrease in size). Treatment response was correlated with tumor and clinical characteristics. RESULTS: Tumors in 8 of the 15 patients studied (53%) responded at 3 months, with 47% (7 of 15 patients) demonstrating tumor stabilization and 6% (1 of 15 patients) demonstrating a decrease in tumor size. The mean duration of response was 25.0+/-6.1 months (range, 5.5-54.1 months). Six of the eight responders were continuing to respond at the time of last follow-up. Tumor response did not correlate with any clinical parameter (e.g., tumor extent, fasting gastrin, or acid secretory rates). However, slow-growing tumors were more likely to respond prior to treatment (86% vs. 0%) (P < 0.0014). During follow-up (range, 4-8 years), 25% of the responders died compared with 71% of the nonresponders, a difference that approached statistical significance (P = 0.10). Two patients (13%) developed serious side effects that required the withdrawal of octreotide. CONCLUSIONS: Octreotide is an effective antitumor treatment in patients with progressive malignant gastrinoma. In approximately 50% of these patients octreotide has an antigrowth effect; treatment is associated with a low incidence of serious side effects compared with other antitumor treatments commonly used and, in contrast to many studies, the growth response is long-lasting. The results of the current study suggest that octreotide treatment should replace chemotherapy as the standard treatment for these patients, especially those patients with slow-growing tumors. Additional studies involving larger numbers of patients will be needed to determine a convincing effect on survival.